Aaron Bloomer was named Chief Financial Officer of Resmed Inc, succeeding Brett Sandercock, effective May 4, 2026. As of November 6, 2026, Resmed Inc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 30, 2026 to August 17, 2026, naming 2 appointments and 2 departures (Form 8-K, April 30, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Resmed Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Resmed Inc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-30 to 2026-08-17. They name 3 people, with 2 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Resmed Inc files it.
Also on the record for Resmed Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 7, 2026 | Stake report, Schedule 13G, by AustralianSuper Pty Ltd | 5.7% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 8.21% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.41% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 13.66% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Resmed Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Resmed Inc and the records around it.
Resmed Inc elsewhere on the record
Companies that share a holder
- AustralianSuper Pty Ltd also filed stake reports on 2 other companies: QXO, Inc. (Aug 2025)
- Vanguard Portfolio Management also filed stake reports on 941 other companies: Newmark Group Inc (Nov 2026), A10 Networks Inc (Oct 2026), ADT Inc (Oct 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Watch Resmed Inc
Get an email when Resmed Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Resmed Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Resmed Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Resmed Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-17 | Out | Director | 8-K, 2026-08-17 | ||
| 2026-04-30 | Out | Chief Financial Officer | 8-K, 2026-04-30 | ||
| 2026-04-30 | In | Chief Financial Officer | 2026-05-04 | 8-K, 2026-04-30 | |
| 2026-04-30 | In | Principal Financial Officer | 8-K, 2026-04-30 |
Who leads Resmed Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Ronald Taylor, departure reported (filed 2026-08-17). No successor is named in these filings.
- Chief Financial Officer: Aaron Bloomer, appointed, effective 2026-05-04 (filed 2026-04-30).
- Principal Financial Officer: Aaron Bloomer, appointed (filed 2026-04-30).
New leaders reset buying decisions — get the Full Report on Resmed Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Resmed Inc, with the record behind each one.
Find candidates like Director at Resmed IncEvery change, in the filing's words
Departing: Ronald Taylor, Director
On August 13, 2026, Ronald Taylor, a director of Resmed, informed the Board that he will not stand for election at Resmed's 2026 annual meeting of stockholders (the "Annual Meeting") and intends to retire from the Board, effective at the Annual Meeting, which is expected to be held on November 18, 2026.
- Mr. Taylor's intention to retire is not due to any disagreement with Resmed on any matter relating to Resmed's operations, policies or practices.
- In connection with Mr. Taylor's retirement, the Board approved the appointment of Carol Burt as lead director, effective November 15, 2026.
Departing: Brett Sandercock, Chief Financial Officer
On April 30, 2026, ResMed Inc. (the "Company") announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.
Appointed: Aaron Bloomer, Chief Financial Officer, effective 2026-05-04
On April 30, 2026, the Company also announced it appointed Aaron Bloomer, age 40, as Chief Financial Officer, effective May 4, 2026.
Appointed: Aaron Bloomer, Principal Financial Officer
Mr. Bloomer will serve as our Principal Financial Officer and Principal Accounting Officer.
- Mr. Sandercock will continue to serve as Chief Financial Officer until May 4, 2026, immediately following which he will become Special Advisor to Mick Farrell, Chairman and Chief Executive Officer through December 31, 2026.
- Mr. Sandercock will continue to receive his current salary, benefits and vesting of long-term equity incentives and will remain eligible for a six month, pro-rata payment of his short-term incentive for fiscal year 2027.
- From January 1, 2027, through December 31, 2027, Mr. Sandercock will continue as Special Advisor to Mr. Farrell in a consulting role.
- During the consulting period he will remain eligible for continued vesting of outstanding equity awards in accordance with the ordinary terms of such equity grants and our equity incentive plans.
- Mr. Sandercock's decision to retire did not result from any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- Mr. Bloomer most recently served as Executive Vice President and Chief Financial Officer of Exact Sciences Corporation (NASDAQ: EXAS), where he led global finance and served as a key advisor to the CEO and Board.
- Prior to Exact Sciences, Mr. Bloomer held senior finance leadership roles at Baxter International Inc. (NYSE: BAX), a global medical device company, and 3M Company (NYSE: MMM), a global industrial, consumer and safety products company.
Tools for this story
Each opens in a new tab, filled in for Resmed Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.